Welcome to our dedicated page for Barinthus Biotherapeutics news (Ticker: BRNS), a resource for investors and traders seeking the latest updates and insights on Barinthus Biotherapeutics stock.
Barinthus Biotherapeutics plc reports clinical, corporate and capital-structure developments as a clinical-stage immunology and inflammation company traded through American Depositary Shares under BRNS. Its news centers on immune tolerance therapies, including VTP-1000, an investigational injectable antigen-specific tolerance immunotherapy for celiac disease that uses the company’s SNAP-TI platform to co-deliver gluten-derived peptide antigens and rapamycin in nanoparticles.
Company updates also cover operating and financial results, shareholder voting matters, governance developments, material agreements and program updates involving VTP-300 for chronic hepatitis B, VTP-850 for prostate cancer and other viral vector-based assets. News about BRNS may also include ADR-related security disclosures and Nasdaq capital-market matters tied to the company’s public listing.
Barinthus Bio (NASDAQ: BRNS) reported Q1 2026 results and corporate updates on April 30, 2026. The company is advancing a proposed merger with Clywedog expected mid-2026, intends to rename the combined company Clywedog Therapeutics Holdings, Inc. (ticker CLYD), and expects cash runway through 2027.
Q1 cash was $67.2M. R&D fell to $3.6M from $8.3M; net loss was $5.5M (loss per share $(0.14)). VTP-1000 multiple ascending dose data are expected in H2 2026.
Barinthus Bio (NASDAQ: BRNS) reported 2025 results and announced a proposed all-stock combination with Clywedog, expected to close in Q2 2026 and trade as CLYD. Cash was $71.9 million at December 31, 2025, with an estimated runway through 2027.
VTP-1000 Phase 1 multiple ascending dose data are expected in H2 2026; single ascending dose data showed tolerability and pharmacodynamic T cell recognition.
Barinthus Bio (NASDAQ: BRNS) reported Phase 1 AVALON SAD results for VTP-1000 in adults with celiac disease showing a dose-dependent pharmacological effect and good tolerability.
The SAD enrolled 18 patients across three placebo-controlled, ascending-dose cohorts (NCT06310291); there were no treatment-related serious adverse events. The MAD portion, which includes a gluten challenge, is ongoing with additional data expected in H2 2026. VTP-1000 uses the SNAP-TI platform to co-deliver gluten-derived peptides (wheat, barley, rye) with rapamycin in nanoparticles aimed at promoting immune tolerance.
The company plans to present detailed pharmacology and immunology data at a scientific conference in 2026.
Barinthus Bio (NASDAQ: BRNS) reported Q3 2025 results and corporate updates, including a definitive all-stock merger agreement with Clywedog and clinical updates for VTP-1000.
Key facts: cash of $75.7M as of Sept 30, 2025 (down $12.1M QoQ); R&D expense $5.4M in Q3 vs $8.0M in Q2; impairment of long-lived assets $4.7M in Q3; net loss $14.6M, $(0.36) per share. Single ascending dose data for VTP-1000 expected before end of 2025; MAD data expected H2 2026. Transaction expected to close H1 2026 and the combined company will trade as CLYD with cash runway into 2027.
Clywedog Therapeutics (formerly Barinthus Therapeutics; NASDAQ: BRNS) and Barinthus have signed a definitive merger agreement to form Clywedog Therapeutics, Inc. ChemDiv will continue providing chemistry, computational, and clinical pharmacology support as the combined company advances clinical-stage candidates in Type 1 diabetes (T1D), Type 2 diabetes (T2D) and celiac disease. The merged company is expected to list on Nasdaq under the ticker CLYD upon closing, with transaction closing targeted for the first half of 2026. The portfolio includes three clinical-stage assets and multiple near-term data milestones; ChemDiv says its services helped progress discovery programs to clinic in less than three years.
Barinthus Biotherapeutics (NASDAQ: BRNS) announced a strategic merger with private company Clywedog Therapeutics in an all-stock transaction. The combined entity will focus on developing treatments for metabolic and autoimmune diseases, featuring three clinical-stage candidates targeting Type 1 Diabetes, Type 2 Diabetes, and Celiac Disease.
The merger will result in Clywedog shareholders owning 66% of the combined company, with Barinthus shareholders holding the remaining 34%. The combined company, to be renamed Clywedog Therapeutics, will trade on NASDAQ as "CLYD" and expects four key clinical milestones within 18 months post-closing. The transaction, backed by OrbiMed and Torrey Pines, is expected to close in H1 2026, with a cash runway extending through 2027.
Barinthus Bio (NASDAQ: BRNS) reported Q2 2025 financial results and provided updates on its clinical programs. The company ended Q2 with $87.8 million in cash, projecting runway into 2027. Key developments include the initiation of the final cohort in the Phase 1 AVALON trial's Single Ascending Dose (SAD) portion for VTP-1000 in celiac disease, with data expected in early Q4 2025.
Q2 financial highlights show R&D expenses of $8.0 million (down from $8.3M in Q1) and G&A expenses of $15.4 million (up from $12.6M in Q1). The company reported a net loss of $21.1 million ($0.52 per share). The VTP-850 prostate cancer trial completed with encouraging immunogenicity data, and the company is actively seeking partners for multiple programs.
Barinthus Bio (NASDAQ: BRNS) has reported its full year 2024 financial results and corporate updates, highlighting its strategic transformation into an immunology and inflammatory disease-focused company. The company's lead asset, VTP-1000, a potentially curative immunotherapy for celiac disease, is progressing with first data expected in Q3 2025.
Key financial highlights include:
- Cash position of $112.4 million as of December 31, 2024
- Revenue of $15.0 million in 2024, up from $0.8 million in 2023
- Net loss of $61.1 million ($1.55 per share)
- Research and development expenses of $42.2 million
The company's SNAP-TI platform shows promise in promoting antigen-specific immune tolerance. In chronic hepatitis B trials, VTP-300 demonstrated encouraging results with eight participants achieving undetectable HBsAg levels. The company's cash runway is expected to extend into 2027.